<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02608476</url>
  </required_header>
  <id_info>
    <org_study_id>CB-03-01/26</org_study_id>
    <nct_id>NCT02608476</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassiopea SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cassiopea SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the safety and efficacy of CB-03-01
      cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial
      acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Actual">February 21, 2018</completion_date>
  <primary_completion_date type="Actual">February 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate in Investigator's Global Assessment (IGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of subjects in each treatment group achieving &quot;success&quot; at Week 12, with &quot;success&quot; defined as an IGA score of &quot;clear (score=0)&quot; or &quot;almost clear (score=1)&quot; and at least a two-point reduction in IGA compared to Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in non-inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in total lesions counts in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in total lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in total lesions counts in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in non-inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in non-inflammatory lesions count in each treatment group at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in inflammatory lesion counts</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percent change from Baseline in inflammatory lesions count in each treatment group at Week 12.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Local Site Reactions</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
    <description>Local Site Reactions (LSRs) including telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, stinging/burning, and pruritus scored by frequency and severity at every visit (Baseline, Weeks 4, 8, and 12).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">732</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CB-03-01 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CB-03-01 cream, 1% applied twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01 cream, 1%</intervention_name>
    <description>CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.</description>
    <arm_group_label>CB-03-01 cream</arm_group_label>
    <other_name>cortexolone 17α-propionate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle cream</intervention_name>
    <description>Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.</description>
    <arm_group_label>Vehicle cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is male or non-pregnant female, 9 years of age or older. Females must be
             post-menopausal, surgically sterile, or using highly effective birth control methods.
             Women of child-bearing potential must have a negative urine pregnancy test (UPT) at
             the Screening/Baseline Visit.

          2. Subject has provided written and verbal informed consent/assent. A subject under 18
             years of age must provide written informed assent and be accompanied by the parent or
             legal guardian at the time of assent/consent signing.

          3. Subject has an Investigator's Global Assessment (IGA) score of 3 (moderate) or 4
             (severe) [0 (clear) to 4 (severe) scale].

          4. Subject has facial acne vulgaris with at least 30 to a maximum of 75 inflammatory
             lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory
             lesions (open and closed comedones).

          5. Subject and parent/guardian (if applicable) are willing to comply with study
             instructions and return to the clinic for required visits.

          6. Subject has used the same type and brand of make-up, other facial products (exclusive
             of RX/OTC acne cleansers) and hair products (e.g., shampoo, gel, hair spray, mousse,
             etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue
             his/her other general skin and hair care products and regimen for the entire study.

        Exclusion Criteria:

          1. Subject is pregnant, lactating, or is planning to become pregnant during the study.

          2. Subject has any skin pathology or condition that could interfere with the evaluation
             of the test products or requires the use of interfering topical or systemic therapy.

          3. Subject has greater than two (2) facial nodules.

          4. Subject has nodulocystic acne.

          5. Subject has any condition which, in the investigator's opinion, would make it unsafe
             for the subject to participate in this research study.

          6. Subject is currently enrolled in an investigational drug or device study.

          7. Subject has received an investigational drug or has been treated with an
             investigational device within 30 days prior to the initiation of treatment (Baseline).

          8. Subject has facial hair that could interfere with the study assessments in the opinion
             of the investigator.

          9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate
             with the investigator due to language problems, poor mental development, or impaired
             cerebral function.

         10. Subject may be unreliable for the study including subjects who engage in excessive
             alcohol intake or drug abuse, or subjects who are unable to return for scheduled
             follow-up visits.

         11. Subject has known hypersensitivity or previous allergic reaction to any of the active
             or inactive components of the test articles.

         12. Subject has the need or plans to be exposed to artificial tanning devices or excessive
             sunlight during the trial.

         13. Subject has used any of the prohibited topical anti-acne treatments or procedures
             prior to the study unless appropriate washout period is documented.

         14. Subject has used used any of the prohibited systemic anti-acne medications prior to
             the study unless appropriate washout period is documented.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Mazzetti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cassiopea S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clear dermatology &amp; Aesthetic Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85255</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson Dermatology</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belleair Research Center</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Dermatology</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Dermatology, PA</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Laser Skin and Vein Institute</name>
      <address>
        <city>Hunt Valley</city>
        <state>Maryland</state>
        <zip>21030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group, LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Dermatology and Laser Specialists</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3521</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3523</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3525</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3520</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3524</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3519</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3526</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3522</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9923</name>
      <address>
        <city>Batumi</city>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9924</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9921</name>
      <address>
        <city>Tbilisi</city>
        <zip>0145</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9920</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9922</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9925</name>
      <address>
        <city>Zugdidi</city>
        <zip>2100</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4819</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-863</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4814</name>
      <address>
        <city>Czestochowa</city>
        <zip>15-794</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4822</name>
      <address>
        <city>Czestochowa</city>
        <zip>42-217</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4815</name>
      <address>
        <city>Katowice</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4811</name>
      <address>
        <city>Katowice</city>
        <zip>62-069</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4821</name>
      <address>
        <city>Kraków</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4815</name>
      <address>
        <city>Kraków</city>
        <zip>40-611</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4813</name>
      <address>
        <city>Kraków</city>
        <zip>70-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4823</name>
      <address>
        <city>Osielsko</city>
        <zip>86-031</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4816</name>
      <address>
        <city>Rzeszów</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4812</name>
      <address>
        <city>Szczecin</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4818</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4820</name>
      <address>
        <city>Łódź</city>
        <zip>91-334</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4033</name>
      <address>
        <city>Sector 2</city>
        <state>Bucharest</state>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4034</name>
      <address>
        <city>Sector 2</city>
        <state>Bucharest</state>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4031</name>
      <address>
        <city>Sector 3</city>
        <state>Bucharest</state>
        <zip>030303</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4029</name>
      <address>
        <city>Sector 6</city>
        <state>Bucharest</state>
        <zip>062272</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4028</name>
      <address>
        <city>Târgovişte</city>
        <state>Jud. Dambovita</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4036</name>
      <address>
        <city>Bucarest</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4035</name>
      <address>
        <city>Bucharest</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4032</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4037</name>
      <address>
        <city>Iaşi</city>
        <zip>700381</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4030</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8138</name>
      <address>
        <city>Belgrade</city>
        <zip>11050</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8137</name>
      <address>
        <city>Belgrade</city>
        <zip>8137</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 8136</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://usacnestudy.com/</url>
    <description>Study Website</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>November 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2015</study_first_posted>
  <disposition_first_submitted>June 10, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 10, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2019</disposition_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

